Treatment With Nelfinavir or Efavirenz of HIV-Infected Patients Who Have Never Received Anti-HIV Drugs

Status unconfirmed · Phase 4

Conditions studied: HIV Infections

In brief

The purpose of this study is to compare two drugs (nelfinavir \[NFV\] and efavirenz \[EFV\]) used in start-up anti-HIV treatment. Doctors want to see if one is better than the other in extending the time that viral load (level of HIV in the blood) is kept low. The study will also look at the response of the immune system to each drug.

Key facts

Study ID

NCT00005000

Run by

Agouron Pharmaceuticals

People needed

200

Starts

1999-12-01

Last updated by the study team

2005-06-24

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients may be eligible for this trial if they:
• Are HIV-positive.
• Have a CD4 count of at least 100 cells/mm3.
• Have a viral load of at least 5,000 copies/ml.

You may not qualify if…

• Patients may not be eligible for this study if they:
• Have taken any antiretroviral (anti-HIV) agent.

Where it is running

• Agouron Pharmaceuticals Inc — San Diego, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.